PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress DOI Creative Commons

Colleen M. Hayes,

Gina M. Gallucci,

James L. Boyer

и другие.

Hepatology Communications, Год журнала: 2024, Номер 9(1)

Опубликована: Дек. 19, 2024

Primary biliary cholangitis (PBC) and primary sclerosing (PSC) are characterized by the destruction of small bile ducts formation multifocal strictures, respectively, impairing flow. This leads to hepatic accumulation acids, causing liver injury risk progression cirrhosis failure. First-line therapy for PBC is ursodeoxycholic acid, although up 40% treated individuals incomplete responders, there no effective PSC, highlighting need better therapeutic options in these diseases. In addition, pruritus a common symptom cholestasis that has severe consequences quality life often undertreated or untreated. Nuclear receptors pharmacological targets treat due their multifactorial regulation enzymatic pathways, particularly acid metabolism. The peroxisome proliferator-activated receptor (PPAR) significant clinical interest its role regulating synthesis detoxification pathways. PPAR agonism fibrates traditionally been explored PPARα’s expression liver; however, recent expanded focus on newer agonists activate other isoforms, example, δ, γ, alone combination. Several have investigated as second-line people living with PBC, including accelerated United States Food Drug Administration approval elafibranor seladelpar. review evaluates available data efficacy safety five treatment associated namely fenofibrate, bezafibrate, saroglitazar, elafibranor,

Язык: Английский

PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress DOI Creative Commons

Colleen M. Hayes,

Gina M. Gallucci,

James L. Boyer

и другие.

Hepatology Communications, Год журнала: 2024, Номер 9(1)

Опубликована: Дек. 19, 2024

Primary biliary cholangitis (PBC) and primary sclerosing (PSC) are characterized by the destruction of small bile ducts formation multifocal strictures, respectively, impairing flow. This leads to hepatic accumulation acids, causing liver injury risk progression cirrhosis failure. First-line therapy for PBC is ursodeoxycholic acid, although up 40% treated individuals incomplete responders, there no effective PSC, highlighting need better therapeutic options in these diseases. In addition, pruritus a common symptom cholestasis that has severe consequences quality life often undertreated or untreated. Nuclear receptors pharmacological targets treat due their multifactorial regulation enzymatic pathways, particularly acid metabolism. The peroxisome proliferator-activated receptor (PPAR) significant clinical interest its role regulating synthesis detoxification pathways. PPAR agonism fibrates traditionally been explored PPARα’s expression liver; however, recent expanded focus on newer agonists activate other isoforms, example, δ, γ, alone combination. Several have investigated as second-line people living with PBC, including accelerated United States Food Drug Administration approval elafibranor seladelpar. review evaluates available data efficacy safety five treatment associated namely fenofibrate, bezafibrate, saroglitazar, elafibranor,

Язык: Английский

Процитировано

0